Metabolic Discovery Comprehensive Panel
This blood test panel combines glucose, insulin, A1c, lipids, liver, kidney, and inflammation markers to clarify metabolic risk and treatment response.
This panel bundles multiple biomarker tests in one order—your report explains how results fit together.
This is a lab panel, not a single test. It bundles glucose control, insulin signaling, cholesterol particles, liver and kidney function, and inflammation markers so you can see how your metabolism is behaving as a system—especially if you’re tracking prediabetes, type 2 diabetes, or changes on GLP-1/GIP medications.
Do I need this panel?
You may want the Metabolic Discovery Comprehensive Panel if your numbers don’t “match” the way you expect—like a hemoglobin A1c (HbA1c) that looks fine but your fasting glucose runs high, or home glucose readings that look improved while your A1c lags behind. A multi-marker panel can help explain those mismatches by showing both short-term glucose, longer-term glucose exposure, and insulin patterns side by side.
This panel is also useful if you’re changing something meaningful—starting or adjusting GLP-1/GIP therapy, changing carbohydrate intake, increasing activity, or trying to protect muscle while losing weight. When weight changes quickly, single markers can move in confusing ways; a broader panel helps you separate “expected shifts” from signals that need attention (for example, dehydration affecting kidney markers, or rapid fat loss affecting liver enzymes).
You might also consider this panel if you have cardiometabolic risk factors (family history of type 2 diabetes, high blood pressure, fatty liver, high triglycerides, low HDL, or a history of gestational diabetes) and you want a baseline that captures both glucose-insulin physiology and atherogenic (plaque-forming) lipid risk.
This panel supports clinician-directed care and shared decision-making. It can help you ask better questions and track trends, but it is not meant for self-diagnosis or changing prescriptions without medical guidance.
Reference ranges and optimal targets can vary by lab and by your situation (age, pregnancy status, medications, and comorbidities). Interpreting this panel works best when you compare trends over time and review results with a clinician.
Lab testing
Ready to order the Metabolic Discovery Comprehensive Panel?
Schedule online, results typically within about a week
Clear reporting and optional clinician context
HSA/FSA eligible where applicable
Get this panel with Vitals Vault
Vitals Vault lets you order a comprehensive metabolic-focused lab panel so you can see multiple, connected markers from a single blood draw. That matters when you’re trying to understand why you feel stuck (plateaus, fatigue, cravings) or why one lab value doesn’t align with another.
After you get results, you can use PocketMD to organize the story your labs are telling—what looks like insulin resistance versus medication effects, what changes may be expected during weight loss, and which follow-up tests or retest timing make sense. This is especially helpful if you’re monitoring GLP-1/GIP therapy and want a clinician-aligned way to think about dosing changes, side effects, and cardiometabolic risk.
If you’re already tracking glucose at home (fingerstick or CGM), this panel can complement that data by adding longer-term markers (like A1c), fasting insulin, and lipid particle risk markers that home devices can’t provide.
You can also use this panel as a baseline and then retest to confirm whether changes in nutrition, training, sleep, or medications are moving the right markers in the right direction.
- One order covers multiple metabolic, lipid, liver, kidney, and inflammation markers
- Designed for trend tracking (baseline → change → retest)
- PocketMD can help you interpret patterns across the whole panel
Key benefits of the Metabolic Discovery Comprehensive Panel
- Clarifies glucose control by pairing fasting glucose with HbA1c and insulin-related markers rather than relying on one number.
- Helps spot insulin resistance patterns (high insulin, high triglycerides, low HDL, rising ALT) even when glucose is only mildly elevated.
- Adds atherogenic lipid risk context (particle-related markers like ApoB) beyond a basic cholesterol panel.
- Supports GLP-1/GIP therapy monitoring by showing cardiometabolic response and potential tradeoffs (for example, dehydration signals or liver enzyme shifts).
- Provides liver and kidney function markers that matter for medication safety, hydration status, and metabolic health.
- Helps explain weight-loss plateaus by distinguishing energy balance issues from metabolic risk signals (insulin, triglycerides, inflammation).
- Creates a single, comparable baseline so you can track trends over time and discuss next steps with a clinician using the full picture.
What is the Metabolic Discovery Comprehensive Panel?
The Metabolic Discovery Comprehensive Panel is a bundled lab panel that measures multiple blood markers related to glucose regulation, insulin signaling, cholesterol and lipoproteins, liver and kidney function, and systemic inflammation. Instead of treating “metabolic health” as one lab value, the panel looks at several connected systems that often move together.
Metabolic health is largely about how your body handles energy—especially how efficiently you move glucose from the bloodstream into cells, how much insulin you need to do that, and how your liver packages and exports fat (triglycerides and cholesterol particles). When insulin resistance develops, you can see a recognizable pattern across markers: fasting insulin tends to rise, triglycerides often rise, HDL may fall, liver enzymes can drift up, and glucose markers may worsen over time.
If you’re using GLP-1/GIP medications or making major lifestyle changes, the “system view” matters. For example, A1c may improve while LDL-C rises transiently during rapid weight loss, or kidney markers may look worse if you were dehydrated on the day of the draw. A comprehensive panel helps you interpret those shifts in context rather than reacting to a single out-of-range result.
This panel does not replace individualized medical care. It is a practical way to gather the core data that clinicians commonly use to assess cardiometabolic risk, monitor therapy response, and decide whether you need more targeted follow-up testing.
What do my panel results mean?
When several markers are low
“Low” on a metabolic panel usually matters most for a few categories: low fasting glucose can happen with under-eating, prolonged fasting, alcohol use, or glucose-lowering medications; low triglycerides and low ApoB can be a favorable sign of lower atherogenic particle burden; and low liver enzymes are often benign. The key is whether low values fit your situation—if you’re on insulin, sulfonylureas, or aggressive GLP-1/GIP dosing and you see low glucose with symptoms (shakiness, sweating, confusion), that pattern deserves prompt clinical review. If lipids are very low while you’re losing weight quickly, your clinician may also consider nutrition adequacy and whether you’re meeting protein and essential fat needs.
When the pattern looks optimal
An “optimal” pattern is usually consistent across categories: fasting glucose and HbA1c are in a healthy range for you, fasting insulin is not elevated, triglycerides are lower, HDL is adequate, and ApoB (or other atherogenic markers) suggests a lower number of cholesterol-carrying particles. Liver enzymes (ALT/AST) and inflammation markers (like hs-CRP) tend to be low-to-moderate, and kidney markers look stable. If you’re on therapy, an optimal pattern also means the benefits are showing up without red flags—your clinician may focus on maintaining the trajectory and choosing an appropriate retest interval rather than making rapid changes.
When several markers are high
A “high” pattern is most informative when multiple markers point in the same direction. Elevated fasting glucose and/or HbA1c suggests higher average blood sugar exposure, and a high fasting insulin can indicate insulin resistance—especially when paired with high triglycerides and low HDL. If ApoB is elevated, that can signal higher atherogenic particle burden even when LDL-C looks only mildly high. Higher ALT (sometimes with AST) can align with metabolic dysfunction–associated steatotic liver disease (fatty liver), particularly when triglycerides and glucose markers are also elevated. If kidney markers look worse at the same time, dehydration, medication effects, or underlying kidney disease may need to be considered before you interpret the rest of the panel.
Factors that influence your panel results
Your results reflect both biology and context. Recent meals, alcohol, sleep loss, acute illness, and heavy exercise can shift glucose, triglycerides, and inflammatory markers. Rapid weight loss can temporarily change lipids and liver enzymes. Hydration status can meaningfully affect kidney-related markers and can make other values look “concentrated.” Medications are a major driver: GLP-1/GIP drugs, metformin, insulin, statins, thyroid medications, steroids, and some psychiatric medications can all move parts of this panel. Finally, timing matters—HbA1c reflects roughly the prior 2–3 months, while fasting glucose and insulin are more “today-focused.” The most useful interpretation compares categories together and looks at trends across repeat tests.
What’s included in this panel
- Absolute Band Neutrophils
- Absolute Basophils
- Absolute Blasts
- Absolute Eosinophils
- Absolute Lymphocytes
- Absolute Metamyelocytes
- Absolute Monocytes
- Absolute Myelocytes
- Absolute Neutrophils
- Absolute Nucleated Rbc
- Absolute Plasma Cells
- Absolute Prolymphocytes
- Absolute Promyelocytes
- Absolute Reactive Lymphocytes
- Adiponectin
- Albumin
- Albumin/Globulin Ratio
- Alkaline Phosphatase
- Alt
- Ast
- Band Neutrophils
- Basophils
- Bilirubin, Total
- Blasts
- Bun/Creatinine Ratio
- Calcium
- Carbon Dioxide
- Chloride
- Chol/Hdlc Ratio
- Cholesterol, Total
- Creatinine
- Eag (Mg/Dl)
- Eag (Mmol/L)
- Egfr
- Eosinophils
- Ferritin
- Folate, Serum
- Globulin
- Glucose
- Hdl Cholesterol
- Hematocrit
- Hemoglobin
- Hemoglobin A1C
- Insulin
- Iron Binding Capacity
- Iron, Total
- Ldl-Cholesterol
- Ldl/Hdl Ratio
- Leptin
- Lymphocytes
- Mch
- Mchc
- Mcv
- Metamyelocytes
- Monocytes
- Mpv
- Myelocytes
- Neutrophils
- Non Hdl Cholesterol
- Nucleated Rbc
- Plasma Cells
- Platelet Count
- Potassium
- Prolymphocytes
- Promyelocytes
- Protein, Total
- Rdw
- Reactive Lymphocytes
- Red Blood Cell Count
- % Saturation
- Sodium
- T3, Free
- T4, Free
- Triglycerides
- Tsh
- Urea Nitrogen (Bun)
- Vitamin B12
- Vitamin D,25-Oh,Total,Ia
- White Blood Cell Count
Frequently Asked Questions
Do I need to fast for this panel?
Fasting is usually recommended because triglycerides, glucose, and insulin are easiest to interpret when you’ve had no calories for about 8–12 hours. Water is typically fine, and staying hydrated can improve the reliability of kidney-related markers. If you can’t fast, you can still test, but you should interpret glucose, insulin, and triglycerides more cautiously and consider repeating a true fasting draw for trend tracking.
Why can my HbA1c look “okay” when my fasting glucose is high (or the reverse)?
HbA1c reflects your average glucose exposure over roughly 2–3 months, while fasting glucose reflects a single point in time. A mismatch can happen if your glucose is variable (high spikes but normal averages), if you recently changed diet/medications, or if red blood cell turnover is altered (which can shift A1c). Looking at fasting glucose, A1c, and insulin together often clarifies whether the issue is variability, timing, or physiology.
How does this panel help if I’m on a GLP-1 or GLP-1/GIP medication?
GLP-1/GIP therapy can improve glucose control and weight, but you still want to monitor the broader cardiometabolic picture. This panel helps you track glycemic markers (glucose, A1c, insulin), lipid risk (including ApoB), and safety/context markers (kidney and liver tests, inflammation). If something shifts unexpectedly—like kidney markers during nausea/dehydration or lipid changes during rapid weight loss—the panel provides context for a clinician-guided adjustment.
What’s the difference between LDL-C and ApoB, and why are both useful?
LDL-C estimates how much cholesterol is carried inside LDL particles, while ApoB reflects the number of atherogenic particles (each particle carries one ApoB). You can have a “normal” LDL-C but a higher ApoB if you have many smaller particles. For cardiometabolic risk, particle number often adds clarity—especially when triglycerides are high or insulin resistance is present.
Is this panel better than ordering tests one by one?
Ordering a bundled panel can be simpler and more coherent because the markers are meant to be interpreted together and drawn at the same time. It also supports cleaner trend tracking. If you already know exactly what you need (for example, a focused glucose-insulin check), a smaller panel may be enough—but when you’re trying to explain plateaus, mismatches, or overall risk, a comprehensive panel is often more informative.
How often should I repeat this panel?
Retest timing depends on what you’re changing. HbA1c generally needs about 8–12 weeks to show a meaningful shift, while fasting glucose, insulin, and triglycerides can change sooner. Many people retest in 8–12 weeks after a medication or lifestyle change, then space out testing once results are stable. Your clinician can tailor timing based on your baseline risk and treatment plan.